Serum human leukocyte antigen-G and soluble interleukin 2 receptor levels in acute lymphoblastic leukemic pediatric patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5399-5403

  Motawi, Tarek M K ^a,c   Zakhary, Nadia I ^b,c   Salman, Tarek M ^a,d   Tadros, Samer A ^a,e  

^a Faculty of Pharmacy   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d AL AZHAR UNIVERSITY   (Egypt)

^e OCTOBER UNIVERSITY FOR MODERN SCIENCES AND ARTS MSA   (Egypt)

Author keywords

2 receptor; Acute lymphoblastic leukemia; G; Soluble human leukocyte antigen; Soluble interleukin

Indexed keywords

EID: 84874100612     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5399     Document Type: Article

References (41)

1. Arioz DT, Altindis M, Tokyol C, et al (2009). Human papillomavirus typing and soluble interleukin-2 receptor levels in female sex workers with a negative cervical smear result. Int J of Gynaecol Obstet, 106, 210-2.
2. Bien E, Balcerska A (2009). Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma. Scand J Immunol, 70, 490-500.
3. Bien E, Balcerska A (2008). Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13, 1-26.
4. Bien E, Balcerska A. (2003). Interleukin 2 receptor-the structure, function and clinical significance in malignant diseases of adults and children. Postepy Hig Med Dosw, 57, 669-83.
5. Brito-Babapulle F (2003). The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol, 121, 203-23.
6. Cervera I, Herraiz MA, Peñaloza J, Vidart J, Martinez-Laso J (2010). A new allele, HLA-G 010120, is generated by a recombination event between HLA-G*01010101/02 and HLA-G*01010201. Tissue Antigens, 75, 738-40.
7. Eiji O, Tasuke H, Katsumi O, et al (2000). Clinical utility of soluble interleukin-2 receptor in patients with acute lymphoblastic leukemia. Jpn J Med Technol, 49, 1576-9.
8. Elattar I (2007). Cancer statistics, NCI, Egypt 2002-2005.
9. Faderl S, O'Brien S, Pui CH, et al (2010). Adult acute lymphoblastic leukemia: concepts and strategies. Cancer, 1, 1165-76.
10. Fainardi E, Castellazzi M, Stignani M, et al (2011). Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci, 68, 433-51.
11. García-Tuñón I, Ricote M, Ruiz A, et al (2004). Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res, 6, 1-7.
12. González A, Rebmann V, LeMaoult J, et al (2012). The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci, 49, 63-84.
13. Hafiz MG, Rahman MM, Mannan MA (2008). Serum lactate dehydrogenase as a prognostic marker of childhood acute lymphoblastic leukemia. Mymensingh Med J, 17, 169-73.
14. HoWangYin K, Caumartin J, Favier B, et al (2011). Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity. J Immunol, 186, 2210-8.
15. HoWangYin KY, Alegre E, Daouya M, et al (2010). Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci, 67, 1133-45.
16. Jo SA, Hwang SH, Chang CL, et al (2010). Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Ra) in patients with non-Hodgkin's lymphoma. Korean J Lab Med, 30, 600-5.
17. Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M (2007). Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz), 66, 159-66.
18. Katsuya H, Yamanaka T, Ishitsuka K, et al (2012). Prognostic index for acute- and lymphoma-type adult T-cell leukemia/ lymphoma. J Clin Oncol, 30, 1635-40.
19. Kitaoka S, Shiota G, Kawasaki H. (2003). Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology, 50, 1569-74.
20. Ksouri H, Bardi R, Mellouli F, Bejaoui M (2009). HLA-G: an immunoregulatory non classical class I HLA molecule. Arch Inst Pasteur Tunis, 86, 27-38.
21. Le Discorde M, Moreau P, Sabatier P, Legeais JM and Carosella ED (2003). Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol, 64, 1039-44.
22. Ling JY, Sun XF, Yan SL, et al (2007). Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases. Ai Zheng, 26, 418-22.
23. Mallet V, Blaschitz A, Crisa L, et al (1999). HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83 dendritic cells expresses HLA-G as a membranebound and soluble protein. Int Immunol, 11, 889-98.
24. Mitsdoerffer M, Schreiner B, Kieseier BC, et al (2005). Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol, 159, 155-64.
25. Moon Y, Kim Y, Kim M, et al (2004). Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Ann Clin Lab Sci, 34, 410-5.
26. Nakase K, Tsuji K, Tamaki S, et al (2005). Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect and Prev, 29, 256-9.
27. Pavlidis NA, Manoussakis MN, Germanidis GS, Moutsopoulos HM (1992). Serum soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Med Pediatr Oncol, 20, 26-31.
28. Pistoia V, Morandi F, Wang X, Ferrone S (2007). Soluble HLA-G: Are they clinically relevant. Semin Cancer Biol, 17, 469-79.
29. Pui CH (2006). Acute lymphoblastic leukemia, in Childhood Leukemias, 2nd ed. In: Pui CH. Cambridge University Press, New York, p 439.
30. Pui CH, Evans WE (2006). Treatment of acute lymphoblastic leukemia. N Engl J Med, 354, 166-78.
31. Rebmann V, Switala M, Eue I, Grosse-Wilde H (2010). Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study. Hum Reprod, 25, 1691-8.
32. Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V (2011). The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol Life Sci, 68, 341-52.
33. Rouas-Freiss N, Moreau P, Ferrone S and Carosella ED (2005). HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res, 65, 10139-44.
34. Sarmento-Ribeiro AB, Proença MT, Sousa I, et al (2012). A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure. Leuk Res, 36, 1041-8.
35. Sheshgiri R, Rao V, Mociornita A, Ross HJ, Delgado DH (2010). Association between HLA-G expression and C4d staining in cardiac transplantation. Transplantation, 89, 480-1.
36. Singer G, Rebmann V, Chen YC, et al (2003). HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res, 9, 4460-4.
37. Wehner R, Dietze K, Bachmann M, Schmitz M (2011). The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun, 3, 258-63.
38. Wiendl H, Feger U, Mittelbronn M, et al (2005). Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain, 128, 2689-704.
39. Yan WH (2010). HLA-G expression in hematologic malignancies. Expert Rev Hematol, 3, 67-80.
40. Yang J, Zhao SL, Yang XL (2012). Expression of HLA-G and DOI:http://dx.doi.org/10.7314/APJCP.2012.13.11.5399
41. sHLA-G and sIL-2R Levels in Childhood Acute Leukemia Patients IL-10 in patients with acute leukemia. Zhonghua Xue Ye Xue Za Zhi, 33, 135-7.